2019
 
2015
2016
2017
2018
2019
 
2019
 


F&S participated in the initiation of Jiangsu Jiuji Huasheng Pharmaceutical Research Institute Co., Ltd
 
Oct.15th,2019—Nanjing, China—Adhering to the "Innovation as dynamics, differentiation as core" business philosophy and being committed to providing differentiated products with intellectual property solutions and environmentally friendly chemical technology to global customers by comprehensive research and development capabilities, Nanjing F&S PharmaTech Co., Ltd. (hereinafter referred to as F&S) announced that Jiangsu Jiuji Huasheng Pharmaceutical Research Institute Co., Ltd. was jointly initiated by F&S, Professor Zhu Hongjian’s team from University of Melbourne in Australia and Pukou High-tech Industrial Development Zone.

Professor Zhu Hongjian is the Director of the Cancer Signal Research Laboratory of the Department of Surgery, University of Melbourne, Australia, and the Chairman of the Australian Chinese Association of Biomedical Sciences (ACABS). His research focuses on identifying basic molecular process in cell biology and the field of cell signalling pathways of growth factors and cytokines, especially in the role of transforming growth factor-beta (TGF-β) signalling pathway in cancer development. His numerous articles have been published in journals of high impact factors such as Nature Medicine, Nature Communications, and Cell.

Jiangsu Jiuji Huasheng Pharmaceutical Research Institute Co., Ltd. will work on gene therapy and EAAL after its establishment.

About Nanjing F&S Pharmatech Co., Ltd.
Jointly initiated by the core team, Crystal Pharmatech Co., Ltd. and Bank of Nanjing in Oct. 2015, and has completed three rounds of financing. We have 5000 square meters of R&D center and have established a comprehensive in-depth cooperation with Jiangsu Yongda Pharmaceutical Co., Ltd.

For more information of Nanjing F&S Pharmatech Co., Ltd., please visit company website: www.fshpharm.com.

 
 
Copyright © 2014-2015 DEDECMS 方生和医药科技有限公司 版权所有
网站开发:希丁哥